Related Experiment Videos
Using Intralesional Adalimumab for Chronic Refractory Cutaneous Granulomatous Inflammation
Houriah Y Nukaly1, Siddharth Srikakolapu1, Dirk M Elston1
1Dr. Nukaly is from the Division of Experimental Medicine, McGill University Health Centre, Montréal, Québec, Canada. Drs. Srikakolapu and Elston are from the Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston.
Cutis
|August 13, 2026
Summary
Intralesional adalimumab injections offer a novel treatment for chronic granulomatous skin inflammation, especially in sensitive areas. This targeted approach effectively manages inflammation with reduced systemic side effects.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Chronic localized granulomatous dermatoses pose significant treatment challenges.
- Standard therapies are often insufficient or poorly tolerated, particularly in cosmetically sensitive regions.
Purpose of the Study:
- To describe a novel technique using intralesional adalimumab for treating chronic refractory cutaneous granulomatous inflammation.
- To evaluate the efficacy and safety of targeted intralesional tumor necrosis factor (TNF) α inhibition.
Main Methods:
- Intralesional injection of adalimumab was employed to treat patients with chronic refractory cutaneous granulomatous inflammation.
- The technique focused on localized delivery to minimize systemic exposure.
Main Results:
- Intralesional adalimumab demonstrated efficacy in managing chronic refractory cutaneous granulomatous inflammation.
- The localized treatment approach offered therapeutic benefits with potentially reduced systemic adverse effects.
Conclusions:
- Intralesional TNF α inhibition represents a promising targeted therapy for refractory cutaneous granulomatous inflammation.
- This method provides a localized treatment option with potential advantages over systemic therapies.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:12Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...